唐氏综合征相关髓系白血病复发或难治患儿的生存结局
该回顾性分析纳入2000至2021年间国际研究组和儿童肿瘤中心收治的62例以治愈为目的治疗的复发或难治性唐氏综合征相关髓系白血病(r/r ML-DS)患儿,中位诊断至复发时间6.8个月,3年无事件生存(EFS)和总生存(OS)分别为20.9±5.3%和22.1±5.4%。生存与接受造血干细胞移植(HSCT)、首次完全缓解(CR1)持续时间及复发后达到缓解相关。
要点
- r/r ML-DS患儿3年EFS和OS分别为20.9±5.3%和22.1±5.4%,预后仍然不佳。
- 接受HSCT与生存改善相关(HR 0.28),CR1>12个月HR 0.31,复发后达到缓解HR 4.03。
- HSCT前达到完全缓解者3年OS和EFS分别为56.0±11.8%和50.5±11.9%,未达CR者3年OS和EFS为10.0±9.5%。
核心结论
- r/r ML-DS在当前治疗时期预后仍然不佳,可作为当前预后判断和未来干预研究的参照点。
- 需要开展临床试验以改善r/r ML-DS患者的生存。
研究设计与样本
- 对国际研究组和儿童肿瘤中心进行的回顾性分析。
- 纳入2000年至2021年间以治愈为目的接受治疗的62例r/r ML-DS患者。
主要发现
- 中位诊断至复发时间为6.8个月(范围1.1-45.5个月)。
- 3年无事件生存(EFS)为20.9±5.3%,3年总生存(OS)为22.1±5.4%。
- 接受造血干细胞移植(HSCT)与生存相关,风险比(HR)为0.28。
- 首次完全缓解(CR1)持续时间>12个月的HR为0.31,复发后达到缓解的HR为4.03。
- HSCT前达到完全缓解者3年OS和EFS分别为56.0±11.8%和50.5±11.9%,未达完全缓解即接受HSCT者3年OS和EFS为10.0±9.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population. We conducted a retrospective analysis of international study groups and pediatric oncology centers and identified 62 patients who received treatment with curative intent for r/r ML-DS between year 2000 to 2021. Median time from diagnosis to relapse was 6.8 (range, 1.1-45.5) months. Three-year event-free survival (EFS) and overall survival (OS) were 20.9 ± 5.3% and 22.1 ± 5.4%, respectively. Survival was associated with receipt of hematopoietic stem cell transplantation (HSCT) (hazard ratio [HR], 0.28), duration of first complete remission (CR1) (HR, 0.31 for > 12 months) and attainment of remission after relapse (HR, 4.03). Patients who achieved complete remission (CR) before HSCT, had an improved OS and EFS of 56.0 ± 11.8% and 50.5 ± 11.9%, respectively compared to those who underwent HSCT without CR (3-year OS and EFS of 10.0 ± 9.5%). Treatment failure after HSCT was predominantly because of disease recurrence (52%) followed by treatment-related mortality (10%). The prognosis of r/r ML-DS remains dismal even in the current treatment period and serve as a reference point for current prognostication and future interventional studies. Clinical trials aimed at improving the survival of patients with r/r ML-DS are needed.
引用
- Raghuram N, Hasegawa D, Nakashima K, et al. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023. PMID: 36735769. doi:10.1182/bloodadvances.2022009381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。